Published in J Bone Miner Res on October 01, 2010
Comparative gastrointestinal safety of bisphosphonates in primary osteoporosis: a network meta-analysis. Osteoporos Int (2013) 2.05
Towards a diagnostic and therapeutic consensus in male osteoporosis. Osteoporos Int (2011) 1.33
Bone turnover markers: use in osteoporosis. Nat Rev Rheumatol (2012) 1.25
Treatment of osteoporosis in men. Bone (2012) 1.06
Male osteoporosis. Endocrinol Metab Clin North Am (2012) 0.92
Osteoporosis in men. J Osteoporos (2012) 0.88
Osteoporosis in men. Nat Rev Endocrinol (2013) 0.85
Active ingredients are reported more often for pharmacologic than non-pharmacologic interventions: an illustrative review of reporting practices in titles and abstracts. Trials (2013) 0.85
Treatment of primary osteoporosis in men. Clin Interv Aging (2014) 0.84
Role of zoledronic acid in the prevention and treatment of osteoporosis. Clin Interv Aging (2011) 0.82
Treatment of osteoporosis in men with bisphosphonates: rationale and latest evidence. Ther Adv Musculoskelet Dis (2013) 0.81
Clinical experience with intravenous zoledronic acid in the treatment of male osteoporosis: evidence and opinions. Ther Adv Musculoskelet Dis (2013) 0.81
Male Osteoporosis in the Elderly. Int J Endocrinol (2015) 0.81
Comparison of Bone Mineral Density in Lumbar Spine and Fracture Rate among Eight Drugs in Treatments of Osteoporosis in Men: A Network Meta-Analysis. PLoS One (2015) 0.80
The evidence for efficacy of osteoporosis treatment in men with primary osteoporosis: a systematic review and meta-analysis of antiresorptive and anabolic treatment in men. J Osteoporos (2011) 0.80
A randomized phase II trial evaluating different schedules of zoledronic acid on bone mineral density in patients with prostate cancer beginning androgen deprivation therapy. Clin Genitourin Cancer (2013) 0.80
Osteoporosis in men: insights for the clinician. Ther Adv Musculoskelet Dis (2011) 0.79
Biochemical bone turnover markers and osteoporosis in older men: where are we? J Osteoporos (2011) 0.79
Osteoporosis in men: a review. Bone Res (2014) 0.78
Efficacy of intravenously administered ibandronate in postmenopausal Korean women with insufficient response to orally administered bisphosphonates. J Bone Miner Metab (2012) 0.78
Italian association of clinical endocrinologists (AME) position statement: drug therapy of osteoporosis. J Endocrinol Invest (2016) 0.77
Comparative Efficacy of Bisphosphonates to Prevent Fracture in Men with Osteoporosis: A Systematic Review with Network Meta-Analyses. Rheumatol Ther (2016) 0.77
Male osteoporosis: clinical approach and management in family practice. Singapore Med J (2014) 0.77
The difference in serum alkaline phosphatase levels between girls with precocious puberty and those with normal puberty. Ann Pediatr Endocrinol Metab (2013) 0.75
Gender Disparities in Osteoporosis. J Clin Med Res (2017) 0.75
Osteoporosis Treatment Efficacy for Men: A Systematic Review and Meta-Analysis. J Am Geriatr Soc (2016) 0.75
Osteoporosis: Zoledronic acid for osteoporosis treatment--a matter of time. Nat Rev Rheumatol (2010) 0.75
Osteoporosis in men: epidemiology and treatment with denosumab. Clin Interv Aging (2014) 0.75
Zoledronic acid infusion for prevention and treatment of osteoporosis. Int J Womens Health (2010) 0.75
Denosumab is really effective in the treatment of osteoporosis secondary to hypogonadism in prostate carcinoma patients? A prospective randomized multicenter international study. Clin Cases Miner Bone Metab (2017) 0.75
Randomized clinical trial comparing efficacy and safety of brand versus generic alendronate (Bonmax®) for osteoporosis treatment. PLoS One (2017) 0.75
Efficacy of bisphosphonates against osteoporosis in adult men: a meta-analysis of randomized controlled trials. Osteoporos Int (2015) 0.75
Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med (2007) 18.27
Denosumab in postmenopausal women with low bone mineral density. N Engl J Med (2006) 10.02
Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med (2007) 9.83
Bisphosphonates and fractures of the subtrochanteric or diaphyseal femur. N Engl J Med (2010) 6.47
Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res (2010) 6.00
Matrix-embedded cells control osteoclast formation. Nat Med (2011) 5.77
Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res (2013) 5.76
Lasofoxifene in postmenopausal women with osteoporosis. N Engl J Med (2010) 5.60
Effect of selective serotonin reuptake inhibitors on the risk of fracture. Arch Intern Med (2007) 4.68
The effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis: a randomized extension to the HORIZON-Pivotal Fracture Trial (PFT). J Bone Miner Res (2012) 4.15
Bone mineral density thresholds for pharmacological intervention to prevent fractures. Arch Intern Med (2004) 3.93
Managing the care of patients receiving antiresorptive therapy for prevention and treatment of osteoporosis: executive summary of recommendations from the American Dental Association Council on Scientific Affairs. J Am Dent Assoc (2011) 3.76
Comparison of a single infusion of zoledronic acid with risedronate for Paget's disease. N Engl J Med (2005) 3.57
Fracture risk and zoledronic acid therapy in men with osteoporosis. N Engl J Med (2012) 3.51
Osteoporosis and fracture risk in women of different ethnic groups. J Bone Miner Res (2004) 3.37
Parathyroid hormone and teriparatide for the treatment of osteoporosis: a review of the evidence and suggested guidelines for its use. Endocr Rev (2005) 3.01
Control of bone mass and remodeling by PTH receptor signaling in osteocytes. PLoS One (2008) 2.96
Glucocorticoids act directly on osteoblasts and osteocytes to induce their apoptosis and reduce bone formation and strength. Endocrinology (2003) 2.84
Incidence of osteonecrosis of the jaw in women with postmenopausal osteoporosis in the health outcomes and reduced incidence with zoledronic acid once yearly pivotal fracture trial. J Am Dent Assoc (2008) 2.75
Skeletal involution by age-associated oxidative stress and its acceleration by loss of sex steroids. J Biol Chem (2007) 2.73
Two-year treatment with denosumab (AMG 162) in a randomized phase 2 study of postmenopausal women with low BMD. J Bone Miner Res (2007) 2.68
Relation between fractures and mortality: results from the Canadian Multicentre Osteoporosis Study. CMAJ (2009) 2.64
Opposite bone remodeling effects of teriparatide and alendronate in increasing bone mass. Arch Intern Med (2005) 2.60
Canadian consensus practice guidelines for bisphosphonate associated osteonecrosis of the jaw. J Rheumatol (2008) 2.57
Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1-34)] in postmenopausal osteoporosis. J Bone Miner Res (2011) 2.53
Rosiglitazone causes bone loss in mice by suppressing osteoblast differentiation and bone formation. Endocrinology (2004) 2.44
Proteasomal degradation of Runx2 shortens parathyroid hormone-induced anti-apoptotic signaling in osteoblasts. A putative explanation for why intermittent administration is needed for bone anabolism. J Biol Chem (2003) 2.44
Sexual differentiation, pregnancy, calorie restriction, and aging affect the adipocyte-specific secretory protein adiponectin. Diabetes (2003) 2.40
Osteocyte apoptosis is induced by weightlessness in mice and precedes osteoclast recruitment and bone loss. J Bone Miner Res (2006) 2.31
Renal safety of annual zoledronic acid infusions in osteoporotic postmenopausal women. Kidney Int (2008) 2.29
Clinical value of monitoring BMD in patients treated with bisphosphonates for osteoporosis. J Bone Miner Res (2009) 2.24
The incidence of osteonecrosis of the jaw in patients receiving 5 milligrams of zoledronic acid: data from the health outcomes and reduced incidence with zoledronic acid once yearly clinical trials program. J Am Dent Assoc (2010) 2.19
A randomized double-blind trial to compare the efficacy of teriparatide [recombinant human parathyroid hormone (1-34)] with alendronate in postmenopausal women with osteoporosis. J Clin Endocrinol Metab (2002) 2.16
Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: thirty-six-month results of a randomized, double-blind, controlled trial. Arthritis Rheum (2009) 2.16
Population trends in BMD testing, treatment, and hip and wrist fracture rates: are the hip fracture projections wrong? J Bone Miner Res (2004) 2.15
Effects of intravenous zoledronic acid once yearly on bone remodeling and bone structure. J Bone Miner Res (2008) 2.04
Osteoporosis in men: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab (2012) 1.96
Obesity is not protective against fracture in postmenopausal women: GLOW. Am J Med (2011) 1.95
The 2002 Canadian bone densitometry recommendations: take-home messages. CMAJ (2002) 1.92
Bisphosphonate associated osteonecrosis of the jaw. J Rheumatol (2009) 1.90
Bone turnover markers in the management of postmenopausal osteoporosis. Clin Biochem (2009) 1.85
FoxO-mediated defense against oxidative stress in osteoblasts is indispensable for skeletal homeostasis in mice. Cell Metab (2010) 1.81
Bisphosphonate therapy for osteoporosis: benefits, risks, and drug holiday. Am J Med (2012) 1.80
Suppression of autophagy in osteocytes mimics skeletal aging. J Biol Chem (2013) 1.80
Effect of co-morbidities on fracture risk: findings from the Global Longitudinal Study of Osteoporosis in Women (GLOW). Bone (2012) 1.79
Ibandronate and the risk of non-vertebral and clinical fractures in women with postmenopausal osteoporosis: results of a meta-analysis of phase III studies. Curr Med Res Opin (2008) 1.79
The estrogen receptor-alpha in osteoclasts mediates the protective effects of estrogens on cancellous but not cortical bone. Mol Endocrinol (2010) 1.79
Predictive value of low BMD for 1-year fracture outcomes is similar for postmenopausal women ages 50-64 and 65 and Older: results from the National Osteoporosis Risk Assessment (NORA). J Bone Miner Res (2004) 1.76
National Osteoporosis Foundation 2008 Clinician's Guide to Prevention and Treatment of Osteoporosis and the World Health Organization Fracture Risk Assessment Tool (FRAX): what they mean to the bone densitometrist and bone technologist. J Clin Densitom (2008) 1.76
Effects of denosumab on bone histomorphometry: the FREEDOM and STAND studies. J Bone Miner Res (2010) 1.74
Osteocyte apoptosis. Bone (2012) 1.73
Resolution of osteonecrosis of the jaw after teriparatide [recombinant human PTH-(1-34)] therapy. J Rheumatol (2009) 1.70
Rapid loss of hip fracture protection after estrogen cessation: evidence from the National Osteoporosis Risk Assessment. Obstet Gynecol (2004) 1.68
Diagnosis and management of vertebral fractures in elderly adults. Am J Med (2002) 1.68
Connexin 43 is required for the anti-apoptotic effect of bisphosphonates on osteocytes and osteoblasts in vivo. J Bone Miner Res (2008) 1.68
Quantitative ultrasound in the management of osteoporosis: the 2007 ISCD Official Positions. J Clin Densitom (2008) 1.66
Quantifying osteoblast and osteocyte apoptosis: challenges and rewards. J Bone Miner Res (2007) 1.66
White-rot fungi demonstrate first biodegradation of phenolic resin. Environ Sci Technol (2006) 1.64
Bisphosphonates for treatment of osteoporosis: expected benefits, potential harms, and drug holidays. Can Fam Physician (2014) 1.63
Risk factors for treatment failure with antiosteoporosis medication: the global longitudinal study of osteoporosis in women (GLOW). J Bone Miner Res (2014) 1.62
Effect of low-intensity pulsed ultrasound on the cartilage repair in people with mild to moderate knee osteoarthritis: a double-blinded, randomized, placebo-controlled pilot study. Arch Phys Med Rehabil (2012) 1.60
Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass. J Clin Endocrinol Metab (2011) 1.59
Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: four-year results from a randomized clinical trial. J Clin Endocrinol Metab (2002) 1.59
Relationship between changes in bone mineral density and vertebral fracture risk associated with risedronate: greater increases in bone mineral density do not relate to greater decreases in fracture risk. J Clin Densitom (2004) 1.59
Change in lumbar spine BMD and vertebral fracture risk reduction in teriparatide-treated postmenopausal women with osteoporosis. J Bone Miner Res (2006) 1.58
Cancer treatment-induced bone loss in breast and prostate cancer. J Clin Oncol (2008) 1.55
Denosumab treatment in postmenopausal women with osteoporosis does not interfere with fracture-healing: results from the FREEDOM trial. J Bone Joint Surg Am (2012) 1.54
Development and pilot testing of a decision aid for postmenopausal women with osteoporosis. Patient Educ Couns (2002) 1.53
Dysapoptosis of osteoblasts and osteocytes increases cancellous bone formation but exaggerates cortical porosity with age. J Bone Miner Res (2014) 1.52
Intermittent PTH stimulates periosteal bone formation by actions on post-mitotic preosteoblasts. Bone (2008) 1.48
Targeted deletion of a distant transcriptional enhancer of the receptor activator of nuclear factor-kappaB ligand gene reduces bone remodeling and increases bone mass. Endocrinology (2007) 1.47
Impact of denosumab on the peripheral skeleton of postmenopausal women with osteoporosis: bone density, mass, and strength of the radius, and wrist fracture. Menopause (2013) 1.47
Patient adherence to osteoporosis medications: problems, consequences and management strategies. Drugs Aging (2007) 1.44
Empirically based composite fracture prediction model from the Global Longitudinal Study of Osteoporosis in Postmenopausal Women (GLOW). J Clin Endocrinol Metab (2014) 1.41
IL-6 is not required for parathyroid hormone stimulation of RANKL expression, osteoclast formation, and bone loss in mice. Am J Physiol Endocrinol Metab (2005) 1.41
Effects of denosumab on fracture and bone mineral density by level of kidney function. J Bone Miner Res (2011) 1.40
Skeletal histomorphometry in subjects on teriparatide or zoledronic acid therapy (SHOTZ) study: a randomized controlled trial. J Clin Endocrinol Metab (2012) 1.38
Attitudes of women who are currently using or recently stopped estrogen replacement therapy with or without progestins: results of the AWARE survey. J Obstet Gynaecol Can (2004) 1.38
Estrogen receptor-α signaling in osteoblast progenitors stimulates cortical bone accrual. J Clin Invest (2012) 1.36
Glucocorticoids and tumor necrosis factor α increase oxidative stress and suppress Wnt protein signaling in osteoblasts. J Biol Chem (2011) 1.32
Do hip protectors decrease the risk of hip fracture in institutional and community-dwelling elderly? A systematic review and meta-analysis of randomized controlled trials. Osteoporos Int (2005) 1.31
Management of osteoporosis in men: an update and case example. CMAJ (2007) 1.29
Previous fractures at multiple sites increase the risk for subsequent fractures: the Global Longitudinal Study of Osteoporosis in Women. J Bone Miner Res (2012) 1.29
Changes to osteoporosis prevalence according to method of risk assessment. J Bone Miner Res (2007) 1.28
Does alendronate reduce the risk of fracture in men? A meta-analysis incorporating prior knowledge of anti-fracture efficacy in women. BMC Musculoskelet Disord (2005) 1.27
Estrogens attenuate oxidative stress and the differentiation and apoptosis of osteoblasts by DNA-binding-independent actions of the ERalpha. J Bone Miner Res (2010) 1.25
Benefits and risks of bisphosphonate therapy for osteoporosis. J Clin Endocrinol Metab (2012) 1.24
Predicting fractures in an international cohort using risk factor algorithms without BMD. J Bone Miner Res (2011) 1.22
FOXOs attenuate bone formation by suppressing Wnt signaling. J Clin Invest (2013) 1.21
Decreased oxidative stress and greater bone anabolism in the aged, when compared to the young, murine skeleton with parathyroid hormone administration. Aging Cell (2010) 1.21
Bone mineral density in women aged 25-35 years receiving depot medroxyprogesterone acetate: recovery following discontinuation. Contraception (2006) 1.21